Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.675 +0.015 (+0.90%)

Streaming Delayed Price Updated: 11:15 AM EDT, Jul 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,323,300
Open	1.720
Bid (Size)	1.670 (12,600)
Ask (Size)	1.680 (35,800)
Prev. Close	1.660
Today's Range	1.650 - 1.735
52wk Range	0.9842 - 4.460
Shares Outstanding	142,183,418
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

Today 8:30 EDT

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

July 15, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	+24.1%	+24.1%
1 Month	-24.5%	-24.5%
3 Month	-23.5%	-23.5%
6 Month	+9.5%	+9.5%
1 Year	+13.9%	+13.9%

More News

Allogene Therapeutics Announces Planned CEO Succession

May 28, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 26, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Q1 Earnings Call Highlights ↗

May 13, 2026

Via MarketBeat

Allogene (ALLO) Q1 2026 Earnings Transcript ↗

May 13, 2026

Via The Motley Fool

Allogene Therapeutics Q1 2026 Earnings Call Transcript ↗

May 13, 2026

Via Benzinga

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

May 13, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 06, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

April 21, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

April 20, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

April 16, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Thursday's session: gap up and gap down stocks ↗

April 16, 2026

Via Chartmill

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

April 15, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

April 14, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

JPMorgan, Allogene Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 14, 2026

Via Benzinga

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

April 13, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

These stocks are making the most noise in today's session. ↗

April 13, 2026

Via Chartmill

ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology

April 13, 2026

Via AB Newswire

Allogene Therapeutics Stock Hits 52-Week High - Here's Why ↗

April 13, 2026

Via Benzinga

These stocks are gapping in today's session ↗

April 13, 2026

Via Chartmill

Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday ↗

April 13, 2026

Via Benzinga

Which stocks are moving before the opening bell on Monday? ↗

April 13, 2026

Via Chartmill

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

April 13, 2026

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Get insights into the top gainers and losers of Friday's after-hours session. ↗

April 10, 2026

Via Chartmill

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?

Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?

Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?

The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market

What is the current price of Allogene Therapeutics, Inc. - Common Stock?

The current price of Allogene Therapeutics, Inc. - Common Stock is 1.675

When was Allogene Therapeutics, Inc. - Common Stock last traded?

The last trade of Allogene Therapeutics, Inc. - Common Stock was at 07/29/26 11:15 AM ET

What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?

The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 238.16M

How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?

Allogene Therapeutics, Inc. - Common Stock has 238M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.